X4 PHARMACEUTICALS, INC Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Dr. Craig; Other NEO average total compensation $5.63M.
- 2024-12-31: PEO Dr. Ragan; Other NEO average total compensation $1.24M.
- 2023-12-31: PEO Dr. Ragan; Other NEO average total compensation $1.39M.
- 2024-12-31: PEO Dr. Ragan; PEO total compensation $2.15M; PEO compensation actually paid $1.43M; Other NEO average total compensation $1.24M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|
| 2025-12-31 | Dr. Craig | | | $5.63M | $13.67M | $13.43 | | -$79.20M | | 2026-03-20 |
|---|
| 2024-12-31 | Dr. Ragan | | | $1.24M | $1.01M | $73.51 | | -$37.45M | | 2026-03-20 |
|---|
| 2023-12-31 | Dr. Ragan | | | $1.39M | $838.05K | $84.49 | | -$101.17M | | 2026-03-20 |
|---|
| 2024-12-31 | Dr. Ragan | $2.15M | $1.43M | $1.24M | $1.01M | $11.35 | | -$37.45M | | 2025-04-25 |
|---|
| 2023-12-31 | | $2.04M | $1.29M | $1.39M | $838.05K | $13.05 | | -$101.17M | | 2025-04-25 |
|---|
| 2022-12-31 | | $3.87M | $3.30M | $1.86M | $1.61M | $15.44 | | -$93.87M | | 2025-04-25 |
|---|